Viridian Therapeutics, Inc.DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30257% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.DE gross margin
Gross margin is gross profit as a percentage of revenue.
Viridian Therapeutics, Inc.DE's gross margin for the twelve months ending Dec 31, 2016 was 26.7%. For fiscal 2016 it was 26.7%, against 2.6% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 26.7% | +24.1 |
| FY2015 | Dec 31, 2015 | 2.6% | −45.5 |
| FY2014 | Dec 31, 2014 | 48.1% | −1.3 |
| FY2013 | Dec 31, 2013 | 49.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2016 | Dec 31, 2016 | -36.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 36.0% | – |
See a number that looks wrong?